Sorafenib is an oral multi-kinase inhibitor of RAF-1, VEGF, c-KIT, PDGFR, Erk, and FLT3 approved for treating hepatocellular and renal cell carcinomas and off-label use in AML post-HSCT therapy [74,75]. This evidence concerns the gene FLT3 and acute myeloid leukemia.